Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8003049 | 0.98 | MAPT (0.97) | MAPTPOLBAPOBEC3AKDM4ELMNA | |
| SCHEMBL4663932 | 0.93 | MAPT (0.86) | MAPTPOLBAPOBEC3AKDM4ELMNA | |
| Iodide SCHEMBL2987038 | 0.88 | MAPT (0.78) | MAPTPOLBAPOBEC3AKDM4ELMNA | |
| SCHEMBL14403381 | 0.86 | MAPT (0.75) | MAPTPOLBAPOBEC3AKDM4ELMNA | |
| Bromide SCHEMBL6247610 | 0.82 | MAPT (0.71) | MAPTPOLBAPOBEC3AKDM4ELMNA | |
| Bromide SCHEMBL11598353 | 0.80 | MAPT (0.66) | MAPTPOLBAPOBEC3AKDM4ELMNA | |
| Iodide SCHEMBL29039127 | 0.79 | MAPT (0.76) | MAPTPOLBAPOBEC3AKDM4ELMNA | |
| Iodide SCHEMBL31063745 | 0.79 | MAPT (0.76) | MAPTPOLBAPOBEC3AKDM4ELMNA | |
| SCHEMBL8943203 | 0.78 | MAPT (0.96) | MAPTPOLBAPOBEC3AKDM4ELMNA | |
| SCHEMBL13652077 | 0.77 | MAPT (0.73) | MAPTPOLBAPOBEC3AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635090-B1 | Dyeing method using a specific cationic derivative and a compound selected among a specific aldehyde, a specific ketone, a quinone and a di-imino-isoindoline or 3-amino-isoindolone derivative | L'OREAL, S.A. (FR) | 2003-10-21 | — | — | US | claimed |
| US-20230372309-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | KYOTO UNIVERSITY (JP) | 2023-11-23 | — | — | US | disclosed |
| EP-4218818-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | Kyoto University (JP) | 2023-08-02 | — | — | EP | disclosed |
| CN-116234578-A | Alpha 2 adrenoreceptor antagonists | 国立大学法人京都大学 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022065354-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | 国立大学法人京都大学 | 2022-03-31 | — | — | WO | disclosed |
| EP-3085698-B1 | PAIN-RELATED COMPOUND AND MEDICINAL COMPOSITION | UNIV KYOTO (JP) | 2019-11-13 | — | — | EP | disclosed |
| CN-105829291-B | Pain-associated compounds and pharmaceutical compositions | 国立大学法人京都大学 | 2019-05-21 | — | — | CN | disclosed |
| US-9745275-B2 | Pain-related compound and medical composition | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-20170029389-A1 | PAIN-RELATED COMPOUND AND MEDICAL COMPOSITION | KYOTO UNIVERSITY (JP) | 2017-02-02 | — | — | US | disclosed |
| EP-3085698-A1 | PAIN-RELATED COMPOUND AND MEDICINAL COMPOSITION | Kyoto University (JP) | 2016-10-26 | — | — | EP | disclosed |
| CN-105829291-A | Pain-associated compounds and pharmaceutical compositions | 国立大学法人京都大学 | 2016-08-03 | — | — | CN | disclosed |
| EP-0889363-B1 | Near IR sensitive photoimageable/photopolymerizable compositions, media, and associated processes | DU PONT (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6861201-B2 | Near IR sensitive photoimageable/photopolymerizable compositions, media, and associated processes | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040191681-A1 | Near IR sensitive photoimageable/photopolymerizable compositions, media, and associated processes | WEED GREGORY C | 2004-09-30 | — | — | US | disclosed |
| US-6635090-B1 | Dyeing method using a specific cationic derivative and a compound selected among a specific aldehyde, a specific ketone, a quinone and a di-imino-isoindoline or 3-amino-isoindolone derivative | L'OREAL, S.A. (FR) | 2003-10-21 | — | — | US | disclosed |
| US-20020064728-A1 | Near IR sensitive photoimageable/photopolymerizable compositions, media, and associated processes | E.I. DU PONT DE NEMOURS AND COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-0889363-A1 | Near IR sensitive photoimageable/photopolymerizable compositions, media, and associated processes | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372309-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | ADRA2A, ADRB2, ADRA2B | MAPT 2183/4885POLB 1937/4885APOBEC3A 3375/4885 |
| US-20170029389-A1 | PAIN-RELATED COMPOUND AND MEDICAL COMPOSITION | OPRL1, TRPV1, P2RY11 | MAPT 672/4885POLB 3961/4885APOBEC3A 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.